Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT06266091
Other study ID # M70102
Secondary ID
Status Active, not recruiting
Phase Phase 2
First received
Last updated
Start date November 24, 2021
Est. completion date December 31, 2024

Study information

Verified date January 2024
Source Wuhan YZY Biopharma Co., Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A Phase II, Randomized, Open-label, Controlled, Multicenter Study to Evaluate the Efficacy and Safety of M701 in treating Patients with Malignant Ascites Caused by Gastrointestinal or Ovarian Cancer combined with Systemic Therapy.


Description:

The phase II study is a controlled, open-label trial designed to assess the effectiveness and safety of M701 intra-peritoneal infusion for controlling malignant ascites in patients with gastrointestinal and ovarian cancer who are also receiving systemic therapy. A total of 80 patients with malignant ascites caused by gastrointestinal or ovarian cancer will be randomly assigned to two treatment arms in a 1:1 ratio. These patients must have experienced disease progression or intolerance after receiving at least two lines of systemic therapy. Both treatment arms will receive the systemic therapy, but the test arm will additionally receive M701 intra-peritoneal infusion, while the control arm will undergo paracentesis only. The primary endpoint of the study will be the puncture-free survival, which evaluates the efficacy of M701 in controlling malignant ascites. Secondary endpoints include the objective response rate (ORR) of malignant ascites, progression-free survival (PFS), overall survival (OS), quality of life (QOL), and safety profiles. The number of EpCAM-positive cells in the malignant ascites will be measured using flow cytometry before and after treatment with M701.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 80
Est. completion date December 31, 2024
Est. primary completion date March 31, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Able to understand and voluntarily sign the written informed consent form. - Histologically or pathologically confirmed epithelial malignancies, including advanced gastric cancer or colorectal cancer that has failed at least two lines of treatment, or platinum-resistant advanced ovarian cancer, primary peritoneal carcinoma, or fallopian tube carcinoma. - Clinical diagnosis of malignant ascites with a moderate or higher amount of ascites. Moderate or higher is defined as having a volume of ascites =1L based on CT assessment or actual drainage of =1L. - The time interval between the most recent anti-tumor treatment and the first dose of M701 must meet the following criteria: Intraperitoneal treatment: =2 weeks since the most recent intraperitoneal treatment. - Adverse events (AEs) from previous treatments have recovered to grade =1 (excluding other AEs deemed by the investigator not to affect the safety of the study drug, such as hair loss). - Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-2. Estimated survival time =8 weeks. - Organ function levels must meet the following requirements: Hematology: Absolute neutrophil count (ANC) =1.5 × 10^9/L, platelets =80 × 10^9/L, hemoglobin =8.5 g/dL, lymphocyte ratio (lymphocyte count/leukocyte count) =10% (without transfusion within 14 days). Liver function: Total bilirubin =1.5 times the upper limit of normal (ULN), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =3 times ULN (AST and ALT =5 times ULN allowed in the presence of liver metastasis). Serum albumin =28 g/L. Renal function: Serum creatinine =1.5 times ULN. Exclusion Criteria: - Patients who have previously received M701 or any antibody-based drugs targeting EpCAM and/or CD3 within the 4 months prior to the first dose. - Patients with microsatellite instability-high (MSI-H)/deficient mismatch repair (dMMR) colorectal cancer who have not previously received immunotherapy. - Patients who have undergone major surgery within the 4 weeks prior to the first dose. - Patients with extensive liver metastases (tumor volume occupying approximately >70% of total liver volume). - Active infections requiring intravenous antibiotics within 14 days before the first dose. - Severe diarrhea (CTCAE grade =2). - Severe respiratory distress requiring oxygen therapy. - Active autoimmune diseases, except for the following conditions that are allowed for screening: type 1 diabetes, controlled hypothyroidism with replacement therapy only, skin diseases that do not require systemic treatment? - Other severe medical conditions that may limit the patient's participation in the trial? - Impaired cardiac function with New York Heart Association (NYHA) class 3 or 4. - Occurrence of complete intestinal obstruction within 30 days before the first dose, or diagnosis of incomplete intestinal obstruction deemed unsuitable for participation in the trial based on symptoms and signs as determined by the investigator. - Inability to adequately drain ascites due to objective reasons (including loculated ascites). - Confirmed portal vein obstruction. - History of immunodeficiency, including positive HIV test. - Active hepatitis B virus infection, active hepatitis C virus infection, active syphilis, or positive HIV antibody. - Pregnant or lactating women. - Patients with fertility requirements during or within 6 months after treatment. - Known history of neurological or psychiatric disorders deemed by the investigator to affect cognitive function or compliance, including unstable epilepsy, dementia, schizophrenia, etc.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
M701
Intra-peritoneal infusion of M701 combined with system therapy
paracentesis
paracentesis combined with system therapy

Locations

Country Name City State
China The First Medical Center of Chinese PLA General Hospital Beijing Beijing

Sponsors (1)

Lead Sponsor Collaborator
Wuhan YZY Biopharma Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Puncture-free survival, PuFS The time to the next puncture/drainage or death From the time of 4th dosing (Day 18) to the next puncture/drainage or death (up to 6 months)
Secondary objective response rate (ORR) of malignant ascites The change of precentage of malignant ascites volume from the baseline by the image evaluation From the time of 4th dosing (Day 18) to the next puncture/drainage or death (up to 180 days)re/drainage or death (up to 6 months)
Secondary Progression-free Survival, PFS The time to disease progression assessed by the imaging evaluation or toxicity or death From the time of first dosing (Day 1) until disease progression or toxicity intolerance or death (up to 6 months).
Secondary Overall survival, OS The time to death From the time of first dosing (Day 1) until death (up to 6 months).
Secondary Quality of Life, QoL Using the QLQ-C30 Scale to score the quality of life at every visit, which includes 3 parts: global health status(2-14, higher is better), funtional status(16-64, lower is better), symptom scale(12-48, lower is better), From the time of first dosing (Day 1) until the EOT (up to 6 months).
Secondary Safety profiles frequency, relationship and seriousness of adverse events From the time of first dosing (Day 1) until one month after the EOT (up to 6 months).
Secondary Positive rate of ADA and Nab in serum The positive rate of Anti-Drug Antibody (ADA) and Neutralizing antibody (Nab) in the serum during the study From the time of first dosing (Day 1) until the EOT (up to 6 months).
Secondary The EpCAM expression in ascites Measure the count of EpCAM postive cells in the ascites before and after M701 treatment From the time of first dosing (Day 1) until the EOT (up to 6 months).
Secondary Trough serum concentration (Ctrough) The lowest concentration of M701 in the serum in one treatment cycle 6 months (anticipated)
Secondary Peak serum concentration (Cmax) The highest concentration of M701 in the serum in one treatment cycle 6 months (anticipated)
See also
  Status Clinical Trial Phase
Recruiting NCT06200376 - A Clinical Study of Intraperitoneal T3011 Given as a Single Agent in Patients With Malignant Ascites Induced by Advanced Colorectal Cancer Phase 1
Completed NCT04051112 - Study With SCB-313 (Recombinant Human TRAIL-Trimer Fusion Protein) for Treatment of Malignant Ascites Phase 1
Completed NCT00836654 - Study in EpCAM Positive Patients With Symptomatic Malignant Ascites Using Removab Versus an Untreated Control Group Phase 2/Phase 3
Not yet recruiting NCT05501340 - PD-1 Inhibitor Intraperitoneal Perfusion Combined With PRaG Therapy for Malignant Ascites Phase 1/Phase 2
Not yet recruiting NCT03550560 - EUS-Guided Drainage of Refractory Malignant Ascites
Recruiting NCT04501744 - A Study of M701 (EpCAM and CD3) in Malignant Ascites Phase 1
Terminated NCT00028782 - EF5 in Detecting Oxygen Level and Blood Vessels in Tumor Cells of Patients Undergoing Photodynamic Therapy for Intraperitoneal or Pleural Cancer N/A
Recruiting NCT05477927 - Dual-targeting VEGFR1 and PD-L1 CAR-T for Cancers Patients With Pleural or Peritoneal Metastases Phase 1
Withdrawn NCT04076566 - Malignant Ascites Alfapump® Study
Enrolling by invitation NCT01854866 - Safety and Effectiveness Study of Tumor Cell-derived Microparticles to Treat Malignant Ascites and Pleural Effusion Phase 2
Recruiting NCT03230708 - Clinical Study of Autologous Erythrocytes Derived MPs Packaging MTX Peritoneal Perfusion to Treat Malignant Ascites Phase 1/Phase 2
Completed NCT01327235 - Endostar and/or Cisplatin for Treatment of Malignant Pleural Effusion or Ascites Phase 2
Recruiting NCT06432296 - Treatment of Malignant Ascites Caused by Advanced Epithelial Solid Tumors With M701 Bispecific Antibody Phase 3
Not yet recruiting NCT04985357 - Defining the Clinical Potential of Mass Response as a Biomarker for Patient Tumor Sensitivity to Drugs
Terminated NCT02496286 - Feasibility Study of Intraperitoneal Bevacizumab for Palliation of Intractable Malignant Ascites Phase 1
Completed NCT01532427 - ALFApump System Post Marketing Surveillance Registry
Completed NCT00326885 - Study of the Trifunctional Antibody Catumaxomab to Treat Recurrent Symptomatic Malignant Ascites Phase 2
Recruiting NCT02530398 - A Tolerance Trial of Cinobufacini Injection Intraperitoneal Perfusion on Digestive System Cancer With Ascites Phase 1
Withdrawn NCT00908219 - A Study of Bevacizumab to Prevent Malignant Ascites Phase 2
Recruiting NCT06016179 - Tocilizumab Delivered Via Pleural and Peritoneal Catheters in Patients With Advanced Metastatic Cancer Phase 1